COO
The Cooper Companies Inc
Q2 2025 Report
The Cooper Companies Inc (COO) Q2 2025 Financial Results: Steady Growth in a Dynamic Market...
Read full report
Executive Summary
In Q4 2024, The Cooper Companies Inc (COO) achieved significant financial milestones with total revenues reaching $1.018 billion, a 10% increase year-over-year driven primarily by strong sales in CooperVision's daily silicone hydrogel lenses and CooperSurgical's fertility products. Notably, CooperVision and CooperSurgical reported yearly record revenues, bolstering the company’s market leadership in contact lenses. However, management noted unexpected softness in U.S. sales towards the end of the quarter, which has necessitated a cautious outlook for fiscal year 2025. Despite these challenges, The Cooper Companies is focused on expansion initiatives and increased product availability, positioning itself for continued growth.
Key Performance Indicators
Revenue
1.02B
QoQ: 1.56% | YoY:9.85%
Gross Profit
627.50M
61.62% margin
QoQ: 2.43% | YoY:3.46%
Operating Income
198.40M
QoQ: 3.06% | YoY:46.20%
Net Income
117.50M
QoQ: 12.23% | YoY:39.05%
EPS
0.59
QoQ: 11.32% | YoY:37.21%
Revenue Trend
Margin Analysis
Key Insights
**Revenues:** $1.018 billion, up 10% YoY, or 7% organically. **Net Income:** $117.5 million, up 39.05% YoY with diluted EPS of $0.58. **Gross Profit Margin:** Increased to 61.6% from 61.4% prior. **Operating Margin:** Improved to 19.4%. **Cash Flow from Operations:** $268 million. **Free Cash Flow:** $128 million. **Net Debt:** Reduced to $2.48 billion, showing a healthier balance sheet with a leverage ratio of 1.94x. **Key Competitors Performance:** Johnson & Johnson and Bausch reported dou...